DDrare: Database of Drug Development for Rare Diseases

Searched query = "Biliary atresia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = A4250; Bicarbonate Ringer's solution; Cefoperazone; Chloride; Corticosteroids; Cysteine; Desflurane; Desflurane anesthetics; Dexamethasone; Dimethyl fumarate; Eicosapentaenoic acid; Epadel; Filgrastim; Gold; Granulocyte Colony-Stimulating Factor; ICG Pulsion; ICG-Pulsion 25mg; Indocyanine green; Intravenous immunoglobulin (IVIG); Lactated Ringer; Lactobacillus casei rhamnosus (Lcr35); MARALIXIBAT CHLORIDE; Magnesium; Magnesium gluconate; Magnesium sulfate; Maralixibat; Meloxicam; Methylprednisolone; N-Acetyl cysteine; Neomycin; Normal saline; OBETICHOLIC ACID; OCA; OCA 0.1 mg; OCA 1.5mg; OCA 5mg; Obeticholic acid; Ocaliva; Odevixibat; Oral Vancomycin; Other Crystalloid; Pentoxifylline; Prednisolone; Propanolol; Propofol; Rifaximin; Rituximab; Rocuronium; Sevoflurane; Sevoflurane anesthetics; Sulfate; UDCA; Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation; VO4CX; Vancomycin; [A4250]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01854827 (ClinicalTrials.gov)	October 2013	27/9/2012	Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia	A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia	Biliary Atresia	Drug: Intravenous immunoglobulin (IVIG)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	N/A	120 Days	All	30	Phase 1;Phase 2	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01854827
(ClinicalTrials.gov)

October 2013

27/9/2012

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia

Biliary Atresia

Drug: Intravenous immunoglobulin (IVIG)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NULL

Completed

N/A

120 Days

All

Phase 1;Phase 2

United States;Canada